{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:47:55Z","timestamp":1780552075278,"version":"3.54.1"},"reference-count":29,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004231","name":"Adamed Pharma S.A.","doi-asserted-by":"publisher","award":["AMD\/OAB\/2019"],"award-info":[{"award-number":["AMD\/OAB\/2019"]}],"id":[{"id":"10.13039\/501100004231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Solifenacin, a selective muscarinic receptor antagonist, is one of the best-tolerated and most effective medicines that relieve storage symptoms in patients with an overactive bladder (OAB). However, the persistence of solifenacin in daily clinical practice remains far below that reported in clinical trials. This study aimed to analyze the adherence of patients to the therapy and the reasons for solifenacin discontinuation and non-regular use in OAB patients managed by urologists. Data concerning non-compliance and the discontinuation of solifenacin, along with the reasons, were collected during two consecutive visits for 64,049 OAB outpatients. Over the two visits, 81.6% of the patients continued therapy, and 88.6% were taking solifenacin regularly. An age \u2265 75 yrs., the male sex, a rural or small-city dwelling, and a prescription of \u226510 mg predicted therapy continuation. The female sex, a higher education, a short or long duration of an OAB, and a non-idiopathic OAB predicted regular use. The persistence of nycturia and urinary incontinence during therapy predicted both discontinuation and non-regular use. Dissatisfaction with therapy was the most frequent reason for discontinuation. In conclusion, an initial prescription of solifenacin at a low dose reduces the chance of OAB symptom improvement and results in more frequent discontinuation. A high rate of discontinuation related to dissatisfaction suggests unrealistic expectations for OAB patients and insufficient education by urologists.<\/jats:p>","DOI":"10.3390\/ph17010116","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T04:03:30Z","timestamp":1705377810000},"page":"116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists"],"prefix":"10.3390","volume":"17","author":[{"given":"Mateusz","family":"Ma\u0142kowski","sequence":"first","affiliation":[{"name":"Adamed Pharma S.A., 05-152 Czosnow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-8123","authenticated-orcid":false,"given":"Agnieszka","family":"Almgren-Rachtan","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance, Europharma Research & Science Centre Co. Ltd., 40-061 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-5590","authenticated-orcid":false,"given":"Magdalena","family":"Olszanecka-Glinianowicz","sequence":"additional","affiliation":[{"name":"Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6367-7794","authenticated-orcid":false,"given":"Jerzy","family":"Chudek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ch\u0142osta","sequence":"additional","affiliation":[{"name":"Department of Urology, Jagiellonian University Medical College, 31-008 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of Bothersome Overactive Bladder Symptoms on Health-related Quality of Life, Anxiety, Depression, and Treatment Seeking in the United States: Results from EpiLUTS","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","article-title":"The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: Results from the EPIC study","volume":"101","author":"Coyne","year":"2008","journal-title":"BJU Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline Amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J. Urol."},{"key":"ref_7","unstructured":"European Association of Urology (2023, July 16). EAU Guidelines: Urinary Incontinence. Available online: https:\/\/uroweb.org\/guideline\/urinary-incontinence\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2165\/00002018-200528070-00003","article-title":"Improving the Tolerability of Anticholinergic Agents in the Treatment of Overactive Bladder","volume":"28","author":"Dmochowski","year":"2005","journal-title":"Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003088-200948050-00001","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin","volume":"48","author":"Doroshyenko","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17562872211039034","DOI":"10.1177\/17562872211039034","article-title":"Update on the management of overactive bladder","volume":"13","author":"Fontaine","year":"2021","journal-title":"Ther. Adv. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.clinthera.2013.08.017","article-title":"Long-Term Patterns of Use and Treatment Failure with Anticholinergic Agents for Overactive Bladder","volume":"35","author":"Chancellor","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: A UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/aogs.12196","article-title":"Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: Data from the Norwegian Prescription Database","volume":"92","author":"Mauseth","year":"2013","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1007\/s12325-020-01412-z","article-title":"Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries","volume":"37","author":"Aparasu","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_15","first-page":"68","article-title":"Has the cost of anti-muscarinic a key role in the success rate of patients diagnosed with overactive bladder syndrome?","volume":"84","author":"Morosetti","year":"2012","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/ijcp.12783","article-title":"Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: A prospective, multicenter, observational study","volume":"70","author":"Kim","year":"2016","journal-title":"Int. J. Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med. Care"},{"key":"ref_18","first-page":"S121","article-title":"Persistence with overactive bladder pharmacotherapy in a Medicaid population","volume":"11","author":"Shaya","year":"2005","journal-title":"Am. J. Manag. Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/nau.23256","article-title":"Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents","volume":"36","author":"Lua","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2018.09.005","article-title":"Antimuscarinic use and discontinuation in an older adult population","volume":"80","author":"Vouri","year":"2019","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCULATIONAHA.120.052339","article-title":"Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights from the TIMI trials","volume":"143","author":"Lau","year":"2021","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ahj.2013.02.011","article-title":"Gender and racial disparities in adherence to statin therapy: A meta-analysis","volume":"165","author":"Lewey","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/luts.12124","article-title":"Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study","volume":"9","author":"Lee","year":"2017","journal-title":"Low. Urin. Tract Symptoms"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/SPV.0000000000001156","article-title":"Patient Experience of Antimuscarinic Treatment for Overactive Bladder: A Qualitative Exploration of Online Forum Content","volume":"28","author":"Morocco","year":"2022","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"key":"ref_26","first-page":"2430","article-title":"Impact of a health education intervention in overactive bladder patients","volume":"11","author":"Herschorn","year":"2004","journal-title":"Can. J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3810\/pgm.2009.09.2062","article-title":"Solifenacin for Overactive Bladder: Patient-Reported Outcomes from a Large Placebo-Controlled Trial","volume":"121","author":"Toglia","year":"2009","journal-title":"Postgrad. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756287216652030","article-title":"Treatment compliance of working persons to high-dose antimuscarinic therapies: A randomized trial","volume":"8","author":"Kosilov","year":"2016","journal-title":"Ther. Adv. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/SPV.0000000000000215","article-title":"Adherence to Oral Therapy for Urgency Urinary Incontinence: Results from the Anticholinergic Versus Botox Comparison (ABC) Trial","volume":"22","author":"Visco","year":"2016","journal-title":"Female Pelvic Med. Reconstr. Surg."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/1\/116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:47:43Z","timestamp":1760104063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/1\/116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ph17010116"],"URL":"https:\/\/doi.org\/10.3390\/ph17010116","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}